Wednesday, 29 March 2023 to Thursday, 30 March 2023

Novel treatment modality for NSCLC in SK-MES-1 cell line targeting the NF-kB pathway.


L Okwera1; S Kritsula1; BM Samudio2; LJ Byrne1; CM Wilson1
1 Canterbury Christ Church University, UK;  2 Atomwise, United States


Non-small lung cancer (NSCLC) is considered one of the leading causes of death within the UK and is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. NSCLC tends to grow at a slower rate and is less aggressive than small cell lung cancer (SCLC). NSCLC is usually undetectable in its initial stages of growth. 

The nuclear factor kappa beta (NF-kB) is the inflammatory pathway responsible for many cell behaviours such as communication, growth and apoptosis. It has been suggested that this pathway is dysregulated and releases p65 and p50 complexes. This is achieved through phosphorylation into the nucleus to trigger specific cytokines causing the increase of tumour progression in lung cancer which promotes a rapid and uncontrolled proliferation of these cancerous cells. Sortilin (SORT1) is a neurotrophin receptor that has a role in cellular communication of exosomes between cells, in NSCLC, gene expression is dysregulated in cancer when the NF-kB pathway is activated. Therefore, this study investigated whether blocking the NF-kB pathway through a novel compound developed using AI and machine learning would potentially act as a molecular glue for the prevention of activation of inflammatory pathway. The conclusion of the study  determined that the novel compound was confirmed to have potentially anti-cancer properties against the NF-kB pathway.


Hosted By


The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis